Eisai and Pfizer announced that the FDA has accepted for review the New Drug Application (NDA) for once-daily 23 mg Aricept (donepezil HCl extended release tablets) for the treatment of moderate to ...

Watching Alzheimer’s disease steal away the memory, talents and very selves of its victims is hard enough for the people who love them. Now, a new pill formulated by a respected pharmaceutical company ...

Eisai and US partner Pfizer yesterday unveiled plans to move into the field of severe Alzheimer’s disease after it filed an application with the US Food and Drug Administration for its market-leading ...

Aricept (donepezil) is a prescription drug approved to treat dementia related to Alzheimer’s disease. Aricept comes as a tablet that you swallow. It’s usually taken once per day. Aricept contains the ...

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for the Aricept ® Patch ...

GENEVA, SWITZERLAND (4 APRIL 2002) - Results from the first head-to-head study comparing ARICEPT® (donepezil HCl tablets) and Reminyl® (galantamine HBr tablets) demonstrated significantly greater ...

Woodcliff Lake, NJ, and New York, July 23, 2010 - Eisai Inc. and Pfizer Inc [NYSE: PFE] announced today that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose Aricept ...